Fig. 1: Assessment of venetoclax resistance and associated transcriptional and protein changes. | Blood Cancer Journal

Fig. 1: Assessment of venetoclax resistance and associated transcriptional and protein changes.

From: Exploring BCL2 regulation and upstream signaling transduction in venetoclax resistance in multiple myeloma: potential avenues for therapeutic intervention

Fig. 1

A MTT assay results after 72-hour incubation, with viability normalized to untreated control. The viability of parental and venetoclax-resistant MM cell lines is displayed in the top and middle panels. Persistence of resistance after 1 month of venetoclax withdrawal is demonstrated in the bottom panel. B Table summarizing transcriptional changes (from mRNA-seq data) between isogenic and resistance-acquired cell lines, and three patient samples (C, G, and T) pre- and post-VTX exposure; darker colors indicate greater statistical significance. C Western Blot analysis of protein expression in parental and venetoclax-resistant cell lines.

Back to article page